Breaking News

Putin, Poroshenko Agree on Cease-Fire in Ukraine
Tweet TWEET

A Forward Look into The Year Ahead - Research Report on Warner Chilcott Plc., Endo Health Solutions Inc., The Western Union

A Forward Look into The Year Ahead - Research Report on Warner Chilcott Plc.,
Endo Health Solutions Inc., The Western Union Company, Euronet Worldwide, Inc.
                       and The Procter & Gamble Company

PR Newswire

NEW YORK, March 12, 2013

NEW YORK, March 12, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Warner
Chilcott Plc. (NASDAQ: WCRX), Endo Health Solutions Inc. (NASDAQ: ENDP), The
Western Union Company (NYSE: WU), Euronet Worldwide, Inc. (NASDAQ: EEFT) and
The Procter & Gamble Company (NYSE: PG). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Warner Chilcott Plc. Research Report

After separating from Warner-Lambert in 1996, Warner Chilcott has evolved to
become a fully integrated pharmaceutical company with a broad portfolio of
leading branded products. However, Wall Street has not been kind to Warner
Chilcott in the past year. It had put itself on sale early in 2012, much to
investors' delight, but dropped the sale in August. To make matters more
difficult, Warner Chilcott's acne treatment drug Doryx is facing generic
competition, while Enablex and oral contraceptive Loestrin could both lose
their patents by 2015. Nevertheless, Warner Chilcott CFO Paul Herenden
comments that the company still has strong strategies for its key franchises.
Herendeen asserted that the company is working on improved versions of its
existing products and are developing new products such as a Phase 2 product
for rosacea and acne, and a Phase 3 treatment for erectile dysfunction. The
Full Research Report on Warner Chilcott Plc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4c53_WCRX]

--

Endo Health Solutions Inc. Research Report

The patents on Lidoderm patch and Opana ER tablets are due to expire. Lidoderm
had sales of $825 million in 2011 and this accounted for 30 percent of the
company's revenues.

Furthermore, with more deaths arising from painkiller overdose, regulators
have been looking more closely on how painkiller manufacturers have been
handling their products. The company is setting aside $194 million to cover
possible penalties because of a federal investigation into how the company
promoted and sold its Lidoderm patch painkilling drug. The Full Research
Report on Endo Health Solutions Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.Investors-Alliance.com/r/full_research_report/49e0_ENDP]

--

The Western Union Company Research Report

As the largest global money movement and payment services company, Western
Union gets its revenues from charging fees to transfer money all over the
world. The company's large size, solid balance sheet, and sustainable pricing
power give it a strong competitive advantage over its rivals. This advantage
allows Western Union to match competitors' pricing pressures, and prevent new
businesses from forming. Western Union is one of the best examples of
companies today with wide economic moats that are trading at discounts to
their intrinsic values. In an attractive industry, the company's dominant
market share allows significant cost and network advantage. It also has
operating margins about twice the size of its competitors. Trading at a
substantial discount provides the company strong protection against downside
risk, and provides a good chance at earning high returns. As the industry
consolidates, Western Union has opportunity to grow through both increased
market share and expansion into new markets. The company recently ventured
into prepaid cards, providing significant growth opportunities playing to its
strength of wide distribution. Despite its stock losing about a quarter of its
value in 2012, Western Union offered a good 3.70 percent dividend yield. The
company also approved a new share repurchase program of $550 million. These
initiatives can help strengthen investors' confidence in the stock. Shares of
Western Union traded up 3.40 percent on Monday, hitting $13.99. In the
previous quarter, the company has reported 45 cents EPS, meeting analysts'
expectations. Analysts have issued a buy rating with a $12 to $19 price
target. Continuing to build upon its global agent network, it recently
announced the expansion of its Direct-to-Bank service to include China and
Canada. Q1 2013 results will be released on April 22, 2013. The Full Research
Report on The Western Union Company - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.Investors-Alliance.com/r/full_research_report/3b71_WU]

--

Euronet Worldwide, Inc. Research Report

Euronet focuses on expanding its global network. The company has recently
announced the acquisition of Pure Commerce, an Australia-based company
offering cloud-based financial and payment solutions. The acquisition would
allow Euronet to expand its services and operating markets. The company
expects the acquisition to contribute approximately three to four cents to its
annual cash EPS in 2013. On February 15, 2013 it will release its Q4 2012
earnings results. With migration from developing to developed countries
increasing, remittances are becoming more relevant for all major developing
economies in the world. The Full Research Euronet Worldwide, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/3c52_EEFT]

--

The Procter & Gamble Company Research Report

P&G, the world's largest consumer goods producer, recently reported impressive
results for the last three months of 2012, or Q2 2013. The company earned $4.1
billion, up from $1.7 billion earnings during the same quarter in the previous
fiscal year. The impressive results are driven by the company's cost-cutting
efforts as well as the introduction of new products, including Tide Pods and a
new version of the Pantene shampoo. Gaining 1.8 percent in 2012, P&G stands a
better chance of performing better in 2013 than its rivals, including
Colgate-Palmolive. Due to strategic pricing, the company's sales are
increasing. In the long term, it is aiming to increase sales volume while
maintaining higher prices. P&G owns some of the best brands in the world that
are known for trust and quality, allowing it to charge a premium for its
products. Looking ahead, P&G expects to experience stable growth in 2013. The
company repurchased $1.4 billion in stock in the latest quarter, totaling of
$4 billion worth of repurchases since July 2012. P&G expects to repurchase $6
billion by June. Q3 2013 earnings of P&G are tentatively scheduled to be
released on April 24, 2013. The Full Research Report on The Procter & Gamble
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/f3e0_PG]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(408)-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.